SSL International plc

Venus, 1 Old Park Lane, Trafford Park, Urmston, Manchester, M41 7HA , UK
Telephone: +44 (0)8701 222 690
Fax: +44 (0)8701 222 696
WWW: http://www.ssl-international.com
Medical Information Direct Line: +44 (0)161 638 2027
Medical Information e-mail: medical.information@ssl-international.com
Customer Care direct line: +44 (0)161 638 2399
Medical Information Fax: +44 (0)161 615 8819

Summary of Product Characteristics last updated on the eMC: 22/02/2007
SPC Ralgex Cream


Go to top of the page
1. NAME OF THE MEDICINAL PRODUCT

Ralgex Cream.


Go to top of the page
2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Glycol Monosalicylate DAB 10.0% w/w; Methyl Nicotinate BP 1.0% w/w; Capsicum Oleoresin BPC 1973 0.12% w/w.


Go to top of the page
3. PHARMACEUTICAL FORM

Cream.


Go to top of the page
4. CLINICAL PARTICULARS

Go to top of the page
4.1 Therapeutic indications

Symptomatic relief of muscular pain and stiffness, including backache, sciatica, lumbago, fibrositis and rheumatic pain.


Go to top of the page
4.2 Posology and method of administration

Adults and children aged 12 years and over: After trial use, rub into the skin until absorbed. To be applied as required to the affected area. Repeat as necessary up to four times a day. Not to be used on children under 12 years except on medical advice. The elderly: The normal adult directions for use can be followed.


Go to top of the page
4.3 Contraindications

Known hypersensitivity to salicylates or to any of the ingredients of the cream. Injuries involving broken skin.


Go to top of the page
4.4 Special warnings and precautions for use

Some people experience stronger effects with Ralgex than others; the product should be tried on a small area first. Do not apply near the eyes, mouth or on sensitive body areas. Day-to-day variation may occur in the sensitivity of the skin, which is more sensitive after a hot bath or in hot weather.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

None known.


Go to top of the page
4.6 Pregnancy and lactation

No evidence of safety of this product has been determined in pregnancy. It is not necessary to contraindicate this product in pregnancy and lactation provided caution is exercised and the directions for use are followed. However, as with all medicines, the advice of a doctor should be sought before the product is used.


Go to top of the page
4.7 Effects on ability to drive and use machines

None stated.


Go to top of the page
4.8 Undesirable effects

Mild irritation of the skin (reddening, burning sensations and rarely swelling) have been reported, which may become more severe. Rashes have also been rarely reported.


Go to top of the page
4.9 Overdose

Overuse would probably cause localised redness, swelling and burning sensations of the skin owing to the counter-irritant effect of the product. Rashes may also develop. These should subside on withdrawal of the product, but occasionally may require treatment. Where this is indicated, relief would be obtained from gently swabbing the area with gauze or white lint soaked in vegetable oil. Rarely the application of a cream or ointment containing corticosteroid may be necessary. It is most unlikely that even the most excessive use of this product would lead to sufficient percutaneous absorption of active ingredients to cause systemic effects. In the case of accidental oral ingestion, the advice of a doctor should be sought.


Go to top of the page
5. PHARMACOLOGICAL PROPERTIES

Go to top of the page
5.1 Pharmacodynamic properties

Pharmacotherapeutic group: other topical products for joint and muscular pain, ATC code: M02A.

Methyl nicotinate has a counter-irritant effect by a rubefacient action. It readily penetrates the cutaneous barrier to produce vasodilatation and elevation of skin temperature. Capsicum oleoresin has a counter-irritant effect by producing irritation and a transient feeling of warmth. Glycol monosalicylate provides the anti-inflammatory and analgesic action. Clinical data demonstrate that Ralgex Cream provides rapid warming relief for muscular aches and pains.


Go to top of the page
5.2 Pharmacokinetic properties

Glycol monosalicylate and methyl nicotinate are readily absorbed percutaneously.


Go to top of the page
5.3 Preclinical safety data

Not applicable.


Go to top of the page
6. PHARMACEUTICAL PARTICULARS

Go to top of the page
6.1 List of excipients

Polawax; Arlacel 165; Oleyl Alcohol; Dimethicone; Methylhydroxybenzoate; Butylhydroxybenzoate; Goliath Perfume SE 83.0502; Neutralaire D7; Deionised water.


Go to top of the page
6.2 Incompatibilities

None known.


Go to top of the page
6.3 Shelf life

Two years.


Go to top of the page
6.4 Special precautions for storage

Store below 25oC.


Go to top of the page
6.5 Nature and contents of container

Flexible aluminium tubes containing either 40g or 100g of product, internally lacquered and having a white polypropylene screw cap. The tubes are contained in a boxboard carton.


Go to top of the page
6.6 Special precautions for disposal and other handling

None stated.


Go to top of the page
7. MARKETING AUTHORISATION HOLDER

SSL International Plc. Venus, 1 Old Park Lane, Trafford Park, Manchester, M41 7HA


Go to top of the page
8. MARKETING AUTHORISATION NUMBER(S)

PL 17905/0052


Go to top of the page
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

10/12/96, 09/01/02


Go to top of the page
10. DATE OF REVISION OF THE TEXT

September 2006



More information about this product

Link to this document from your website: http://emc.medicines.org.uk/medicine/4487/SPC/Ralgex Cream/




© 2010 Datapharm Communications Ltd

Go to www.medicines.org.uk